Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QLT PhotoTherapeutics (QLTI) -- Ignore unavailable to you. Want to Upgrade?

To: Chris D who wrote (284)	3/10/1998 11:29:00 PM
From: Helmut	Read Replies (1) \| Respond to of 1321

Chris, Thanks for replying to Joe's request for a summary of Christine Charette's valuations of QLT. I've been away for a few days, and you answered the queries better than I could have. QLT's lead on any of the competing treatments is a factor she continues to remind investors of - most recently its two to three year lead on Miravant's photodynamic therapy drug, Purlytin. Given her arguments, I'm always mystified why QLT is trading at such a discount. Is it because it's a Canadian company? Helmut